Patents by Inventor Shigeyuki Iijima
Shigeyuki Iijima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10118959Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: GrantFiled: October 3, 2014Date of Patent: November 6, 2018Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Patent number: 9102739Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: GrantFiled: October 11, 2006Date of Patent: August 11, 2015Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Publication number: 20150098941Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, XENCOR, INC.Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Patent number: 8759025Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: GrantFiled: December 19, 2011Date of Patent: June 24, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20120156724Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: ApplicationFiled: December 19, 2011Publication date: June 21, 2012Inventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Patent number: 8101719Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: GrantFiled: November 11, 2004Date of Patent: January 24, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuka Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20110070614Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Inventors: MASAYUKI TSUCHIYA, SHIGEYUKI IIJIMA, IZUMI SUGO, YASUO SEKIMORI, KENJU UENO, KIYOSHI HABU
-
Publication number: 20110033452Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Patent number: 7867734Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: GrantFiled: October 26, 2005Date of Patent: January 11, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Patent number: 7863042Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: GrantFiled: June 18, 2004Date of Patent: January 4, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kenju Ueno, Kiyoshi Habu
-
Publication number: 20090061485Abstract: The present invention relates to a method of producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited, and it also provides a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed.Type: ApplicationFiled: December 22, 2004Publication date: March 5, 2009Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto
-
Publication number: 20080267979Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: ApplicationFiled: October 11, 2006Publication date: October 30, 2008Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Publication number: 20080166756Abstract: The present invention relates to a method of producing a recombinant protein particularly an antibody using a cell in which the function of a fucose transporter is inhibited. According to the present invention, a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed is provided.Type: ApplicationFiled: October 26, 2005Publication date: July 10, 2008Inventors: Masayuki Tsuchiya, Shigeyuki IIjima, Izumi Sugo, Yasuo Sekimori, Kiyoshi Habu, Masamichi Sugimoto
-
Publication number: 20080124330Abstract: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2/0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.Type: ApplicationFiled: October 26, 2005Publication date: May 29, 2008Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Kiyotaka Nakano, Izumi Sugo, Masamichi Sugimoto, Takahiro Ishiguro, Megumi Tanaka, Shigeyuki Iijima
-
Publication number: 20080107654Abstract: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies.Type: ApplicationFiled: November 11, 2004Publication date: May 8, 2008Inventors: Yasufumi Kikuchi, Shinsuke Uno, Yasuko Kinoshita, Shigeyuki Iijima, Naoshi Fukushima, Masayuki Tsuchiya
-
Publication number: 20070142627Abstract: An antibody (anti-HM1.24 antibody) against HM1.24 antigen in which the alteration of sugar chains resulted in enhanced antibody-dependent cellular cytotoxicity (ADCC), specifically an antibody having a sugar chain that does not contain ?-1,6 core fucose, an antibody having a sugar chain that contains a bisecting N-acetylglucosamine (GlcNAc) structure, or an antibody having a sugar chain that does not contain ?-1,6 core fucose and having a sugar chain that contains a bisecting N-acetylglucosamine (GlcNAc) structure.Type: ApplicationFiled: August 11, 2004Publication date: June 21, 2007Inventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Masamichi Sugimoto
-
Publication number: 20070087005Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.Type: ApplicationFiled: October 14, 2005Publication date: April 19, 2007Inventors: Gregory Lazar, Bassil Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
-
Publication number: 20060246456Abstract: The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited.Type: ApplicationFiled: June 18, 2004Publication date: November 2, 2006Inventors: Masayuki Tsuchiya, Shigeyuki Iijima, Izumi Sugo, Yasuo Sekimori, Kenju Ueno, Kiyoshi Habu